Relationship of Ecosystems and Resolution of New Drug Research and Development
TAO Xiu-mei1, DONG Jiang-ping2, HUANG Lei 3, JIANG De-yuan1*
1.China Food and Drug Administration Institute of Executive Development, Beijing 100073, China; 2.Department of Drug Registration, China Food and Drug Adminstraion, Beijing 100053,China; 3.Beijing Nuokangda Pharmaceutical Technology Co., Ltd., Beijing 100176, China
Abstract��OBJECTIVE Relationship of ecosystems and resolution of new drug research and development is analyzed through a comparison of the clinical needs, industry development policy, enterprise-self factor, listing application mechanism, number and characteristics of new drug in America and China, especially, the market conditions of the me-only, me-better and me-too between America and China is analyzed importantly. The idea that the new drug is studied and developed in China is presented. METHODS The important influencing factors that affected the ecosystems of new drug research and development were analyzed by comparison METHODS and data studies. RESULTS The clinical availability of new drug in America is significant increased recently and over 90% applied new drugs can be finished in a limited time based on the evolution of the innovative ecological environment of new drug research and development from 1993 to 2014, new drugs are approval listing in America and China respectively. CONCLUSION The availability of new drug is very important to a state security. The ecosystem of new drug research and development is very complicated. The relative field in America is more advanced than in China and it is used for reference to the new drug research and development in China.
����÷, ����Ƽ, ����, ����Ԫ. ۻ�鴴��ҩ���з�����̬�����봴��ҩ���з�[J]. �й�ҩѧ��־, 2016, 51(7): 592-597.
TAO Xiu-mei, DONG Jiang-ping, HUANG Lei , JIANG De-yuan. Relationship of Ecosystems and Resolution of New Drug Research and Development. Chinese Pharmaceutical Journal, 2016, 51(7): 592-597.
Targeted Drug Development: Why Are Many Diseases Lagging Behind? [EB/OL]. U.S.Food and Drug Administration [2015-07]. http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm454955.htm.
[2]
FDA.Prescription Drug User Fee Act (PDUFA) of 1992 [ EB/OL]. [2013-04-20]. http://www. fda. gov/for Industry/User Fees/Prescription Drug UserFee/ucml 19253.htm.
[3]
YAO L X,LI M Z,DONG J P,et al. Evolution of FDA��s NDA / BLA review process under PDUFA[J]. Chin J New Drugs(�й���ҩ��־),2013,22(10):1144-1169.
[4]
FDA CDER. Manul of Policies and Procedures,MAPP 6020.3[EB/OL]. [1996-04-22]. http://www. fda. gov. /cder/map/6020-3. pdf.
[5]
GAO L,LIU A L,DU G H. New molecular entity and new drugs R��D[J]. Chin Pharm J(�й�ҩѧ��־),2012, 47(21):1170-1172.
[6]
��62 new drug certificates have been obtained in National Science and Technology Major Projects for ��Major New Drugs Innovation and Development�� ��[EB/OL]. News center of the Ministry of science and technology of the people��s Republic of China, Ministry of science and technology work,[2013-03-01]. http://www. most. gov. cn/kjbgz/201302/t20130228_99870. htm.
[7]
��Opinions on deepening the reform of drug evaluation and approval to further encourage innovation��Release conference [EB/OL]. [2015-11-04]. http://www. sda. gov. cn/WS01/ CL0849/78621. html
[8]
YANG D S,WEI B P. Sino-US comparison of drug application system[J]. J Changchun Univ(������ѧѧ��),2013,23(11):1458-1461.
[9]
DREWS J. Innovation deficit revisited: Reflections on the productivity of pharmaceutical R&D[J]. Drug Discov Today, 1998, 3(11): 491- 494.
[10]
DING J X,ZHAO M. The comparative study on supervision and incentive policies of Sino-US during the innovative drug R��D[J]. Chin J New Drugs(�й���ҩ��־),2009,18(5):387-392.
[11]
YANG L,LIAN G Y,XING H,et al. Research on the R��D incentives of FDA in the new drug registration and approval [J]. Chin J New Drugs(�й���ҩ��־),2012,21(9):964-968.
[12]
LI H Z. The differences between Sino-US new drug evalluation procedure[J]. J Chin Med(��ҩ��),2003,26(8):600-602.
[13]
DONG J P. Introduction for independent evaluation report of FDA NDA firstcycle review performance[J]. Chin J Pharm(�й�ҽҩ��ҵ��־),2009,40(l):71-75.
[14]
WU H Y,DONG J P,SUN L H. FDA Regulation of advisory committees and it��s revelation[J]. Chin Pharm Aff(�й�ҩ��),2009,23 (3):303-306.
2016, Vol. 51 
